SEE THE OPZELURA DIFFERENCE

TREATMENT SUCCESS (IGA-TS*) ACHIEVED AT WEEK 81

Patient 1’s knee with visible red patches indicating inflammation and lesions associated with AD.
Patient 1’s knee with visible red patches indicating inflammation and lesions associated with AD.

Actual clinical trial participant. Individual results may vary.

*IGA-TS is defined as the achievement of clear (IGA 0) or almost clear (IGA 1) skin with at least a 2-point improvement from baseline.2

TREATMENT SUCCESS (IGA-TS*) ACHIEVED AT WEEK 81

Patient 2’s skin before treatment with OPZELURA; red patches indicate inflammation and lesions associated with AD
Patient 2’s skin before treatment with OPZELURA; red patches indicate inflammation and lesions associated with AD

Actual clinical trial participant. Individual results may vary.

*IGA-TS is defined as the achievement of clear (IGA 0) or almost clear (IGA 1) skin with at least a 2-point improvement from baseline.2

View itch data >

IGA=Investigator's Global Assessment; IGA-TS=Investigator's Global Assessment Treatment Success.

References: 1. Data on file. Incyte Corporation. 2021. 2. Opzelura. Prescribing Information. Incyte Corporation; 2021.